20 articles
The Break Wave device shatters kidney stones into passable fragments in 7 of 10 patients, no anesthesia needed, in a clinic setting.
Cyclarity's UDP-003 passed its first human trial with zero serious side effects, successfully flushing toxic 7-ketocholesterol through urine.
Maze Therapeutics' MZE829 reduced kidney damage markers by over 35% in patients with APOL1-mediated kidney disease in Phase 2 trials.
A 1,658-person clinical trial found that even smart bottles, coaching, and cash incentives couldn't prevent kidney stone recurrence.
Telitacicept slashed urinary protein by 59% in 39 weeks, signaling a major advance for a kidney disease affecting millions worldwide.
The FDA updated orlistat's label after linking the OTC weight-loss pill to rare but serious kidney complications including AKI and kidney stones.
Cyclarity Therapeutics reveals clinical data showing UDP-003 can safely excrete 7-ketocholesterol, a root driver of arterial plaque, from the human body.
Cyclarity's UDP-003 shows first human evidence of excreting oxidized cholesterol, pointing toward reversing arterial damage rather than just slowing it.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
A Phase 3 trial shows Humacyte's lab-grown vessel delivers 220 catheter-free days vs 129 for standard fistulas in dialysis patients.
A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.
Baxdrostat blocks aldosterone production directly, cutting systolic BP by ~15 mmHg in resistant hypertension patients who failed other drugs.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
A phase III trial shows saroglitazar helped 57% of primary biliary cholangitis patients achieve biochemical response vs just 10% on placebo.
A large study confirms current CKD diagnostic thresholds hold up under gold-standard kidney testing, while revealing which biomarker combo predicts risk best.
A UC San Diego trial shows ION224 blocks liver fat production, cutting inflammation and scarring in 60% of MASH patients.
New analyses of vutrisiran show consistent benefits in diverse heart amyloidosis patients, with a long-term observational study now underway.
Elysium Health launches Creatine+, blending creatine, HMB, and pomegranate polyphenols to support strength, recovery, and healthy aging.
Tebipenem pivoxil matches IV antibiotics for serious UTIs, potentially eliminating hospital stays for thousands of patients.
